Nitric Oxide Patent Expiration
Nitric Oxide is Used for treating pulmonary hypertension or hypoxia through nitric oxide delivery to the patient. It was first introduced by Mallinckrodt Pharmaceuticals Ireland Ltd
Nitric Oxide Patents
Given below is the list of patents protecting Nitric Oxide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Genosyl | US11672938 | Start-up protocols for nitric oxide delivery device | Jul 22, 2040 | Vero Biotech Inc |
| Inomax |
US9770570 (Pediatric) | Apparatus and method for monitoring nitric oxide delivery | Nov 03, 2036 | Mallinckrodt Ireland |
| Inomax | US9770570 | Apparatus and method for monitoring nitric oxide delivery | May 03, 2036 | Mallinckrodt Ireland |
| Genosyl | US10213572 | Nitrogen dioxide storage cassette | Feb 12, 2036 | Vero Biotech Inc |
| Genosyl | US10737051 | Nitrogen dioxide storage device | Oct 20, 2035 | Vero Biotech Inc |
| Inomax |
US9279794 (Pediatric) | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide | Aug 19, 2035 | Mallinckrodt Ireland |
| Inomax | US9279794 | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide | Feb 19, 2035 | Mallinckrodt Ireland |
| Inomax |
US8291904 (Pediatric) | Gas delivery device and system | Jul 06, 2031 | Mallinckrodt Ireland |
| Inomax |
US8573209 (Pediatric) | Gas delivery device and system | Jul 06, 2031 | Mallinckrodt Ireland |
| Inomax |
US8573210 (Pediatric) | Nitric oxide delivery device | Jul 06, 2031 | Mallinckrodt Ireland |
| Inomax |
US8776794 (Pediatric) | Nitric oxide delivery device | Jul 06, 2031 | Mallinckrodt Ireland |
| Inomax |
US8776795 (Pediatric) | Gas delivery device and system | Jul 06, 2031 | Mallinckrodt Ireland |
| Inomax |
US9265911 (Pediatric) | Gas delivery device and system | Jul 06, 2031 | Mallinckrodt Ireland |
| Inomax |
US9295802 (Pediatric) | Gas delivery device and system | Jul 06, 2031 | Mallinckrodt Ireland |
| Inomax |
US9408993 (Pediatric) | Nitric oxide delivery device | Jul 06, 2031 | Mallinckrodt Ireland |
| Inomax | US8291904 | Gas delivery device and system | Jan 06, 2031 | Mallinckrodt Ireland |
| Inomax | US8573209 | Gas delivery device and system | Jan 06, 2031 | Mallinckrodt Ireland |
| Inomax | US8573210 | Nitric oxide delivery device | Jan 06, 2031 | Mallinckrodt Ireland |
| Inomax | US8776794 | Nitric oxide delivery device | Jan 06, 2031 | Mallinckrodt Ireland |
| Inomax | US8776795 | Gas delivery device and system | Jan 06, 2031 | Mallinckrodt Ireland |
| Inomax | US9265911 | Gas delivery device and system | Jan 06, 2031 | Mallinckrodt Ireland |
| Inomax | US9295802 | Gas delivery device and system | Jan 06, 2031 | Mallinckrodt Ireland |
| Inomax | US9408993 | Nitric oxide delivery device | Jan 06, 2031 | Mallinckrodt Ireland |
| Genosyl | US8607785 | Systems and devices for generating nitric oxide | Jul 14, 2030 | Vero Biotech Inc |
| Genosyl | US11103669 | Nitric oxide therapies | Jun 21, 2030 | Vero Biotech Inc |
| Inomax |
US11931377 (Pediatric) | Methods of administering inhaled nitric oxide gas | Dec 30, 2029 | Mallinckrodt Ireland |
| Inomax |
US8282966 (Pediatric) | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide | Dec 30, 2029 | Mallinckrodt Ireland |
| Inomax |
US8293284 (Pediatric) | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide | Dec 30, 2029 | Mallinckrodt Ireland |
| Inomax |
US8431163 (Pediatric) | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas | Dec 30, 2029 | Mallinckrodt Ireland |
| Inomax |
US8795741 (Pediatric) | Methods for treating patients who are candidates for inhaled nitric oxide treatment | Dec 30, 2029 | Mallinckrodt Ireland |
| Inomax |
US8846112 (Pediatric) | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation | Dec 30, 2029 | Mallinckrodt Ireland |
| Genosyl | US11511252 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) | Sep 21, 2029 | Vero Biotech Inc |
| Genosyl | US10926054 | Systems and devices for generating nitric oxide | Aug 13, 2029 | Vero Biotech Inc |
| Genosyl | US8944049 | Systems and devices for generating nitric oxide | Aug 13, 2029 | Vero Biotech Inc |
| Genosyl | US9604028 | Systems and devices for generating nitric oxide | Aug 13, 2029 | Vero Biotech Inc |
| Inomax | US11931377 | Methods of administering inhaled nitric oxide gas | Jun 30, 2029 | Mallinckrodt Ireland |
| Inomax | US8282966 | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide | Jun 30, 2029 | Mallinckrodt Ireland |
| Inomax | US8293284 | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide | Jun 30, 2029 | Mallinckrodt Ireland |
| Inomax | US8431163 | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas | Jun 30, 2029 | Mallinckrodt Ireland |
| Inomax | US8795741 | Methods for treating patients who are candidates for inhaled nitric oxide treatment | Jun 30, 2029 | Mallinckrodt Ireland |
| Inomax | US8846112 | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation | Jun 30, 2029 | Mallinckrodt Ireland |
| Genosyl | US9701538 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) | Jan 28, 2029 | Vero Biotech Inc |
| Genosyl | US7560076 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) | Apr 21, 2027 | Vero Biotech Inc |
| Genosyl | US7618594 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) | Oct 17, 2026 | Vero Biotech Inc |
| Genosyl | US7947227 | Kit for the conversion of nitrogen dioxide (NO2) to nitric oxide (NO) | Oct 17, 2026 | Vero Biotech Inc |
| Genosyl | US8057742 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Jan 18, 2026
(Expired) | Vero Biotech Inc |
| Genosyl | US10814092 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Oct 17, 2025
(Expired) | Vero Biotech Inc |
| Genosyl | US10124142 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug 18, 2025
(Expired) | Vero Biotech Inc |
| Genosyl | US11291793 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug 18, 2025
(Expired) | Vero Biotech Inc |
| Genosyl | US11383059 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug 18, 2025
(Expired) | Vero Biotech Inc |
| Genosyl | US11554241 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug 18, 2025
(Expired) | Vero Biotech Inc |
| Genosyl | US8226916 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug 18, 2025
(Expired) | Vero Biotech Inc |
| Genosyl | US8609028 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug 18, 2025
(Expired) | Vero Biotech Inc |
| Genosyl | US8821801 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug 18, 2025
(Expired) | Vero Biotech Inc |
| Genosyl | US9522249 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug 18, 2025
(Expired) | Vero Biotech Inc |
| Genosyl | US9956373 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug 18, 2025
(Expired) | Vero Biotech Inc |
| Genosyl | US6758214 | Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment |
Feb 23, 2022
(Expired) | Vero Biotech Inc |
| Inomax |
US6125846 (Pediatric) | Purge system for nitric oxide administration apparatus |
Nov 16, 2017
(Expired) | Mallinckrodt Ireland |
| Inomax |
US5732693 (Pediatric) | Pause control of nitric oxide therapy |
Jun 13, 2017
(Expired) | Mallinckrodt Ireland |
| Inomax |
US5752504 (Pediatric) | System for monitoring therapy during calibration |
Jun 13, 2017
(Expired) | Mallinckrodt Ireland |
| Inomax | US6125846 | Purge system for nitric oxide administration apparatus |
May 16, 2017
(Expired) | Mallinckrodt Ireland |
| Inomax | US5732693 | Pause control of nitric oxide therapy |
Dec 13, 2016
(Expired) | Mallinckrodt Ireland |
| Inomax | US5752504 | System for monitoring therapy during calibration |
Dec 13, 2016
(Expired) | Mallinckrodt Ireland |
| Inomax |
US5558083 (Pediatric) | Nitric oxide delivery system |
May 22, 2014
(Expired) | Mallinckrodt Ireland |
| Inomax | US5558083 | Nitric oxide delivery system |
Nov 22, 2013
(Expired) | Mallinckrodt Ireland |
| Inomax |
US5485827 (Pediatric) | Methods and devices for treating plumonary vasoconstriction and asthma |
Jul 23, 2013
(Expired) | Mallinckrodt Ireland |
| Inomax |
US5873359 (Pediatric) | Methods and devices for treating pulmonary vasoconstriction and asthma |
Jul 23, 2013
(Expired) | Mallinckrodt Ireland |
| Inomax | US5485827 | Methods and devices for treating plumonary vasoconstriction and asthma |
Jan 23, 2013
(Expired) | Mallinckrodt Ireland |
| Inomax | US5873359 | Methods and devices for treating pulmonary vasoconstriction and asthma |
Jan 23, 2013
(Expired) | Mallinckrodt Ireland |
Nitric Oxide's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on Nitric Oxide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
